Langkau ke kandungan utama

Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis

Juga terdapat dalam

Sarcoidosis is a condition that can affect most of the organs in the body, including the lungs, heart, brain, bones, liver and skin. Patients who have severe disease or those who do not respond to treatment with steroids are often given powerful agents that suppress the immune system in an attempt to control the disease. However, these drugs have severe side effects. There is no evidence at the moment that the benefits of these drugs outweigh their side effects.

Latar Belakang

Immunosuppressive and cytotoxic agents have been used as both an alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in the treatment of pulmonary sarcoidosis.

Matlamat

To determine the efficacy of immunosuppressive and cytotoxic agents in the treatment of pulmonary sarcoidosis.

Kaedah Pencarian

CENTRAL, MEDLINE, EMBASE and CINAHL were searched for possible randomised trials and bibliographies were checked for other potentially relevant trials. Searches were current as of April 2006.

Kriteria Pemilihan

Randomised controlled trials comparing an immunosuppressive or cytotoxic therapy with a control in patients with pulmonary sarcoidosis were included in the review.

Pengumpulan Data dan Analisis

Two reviewers independently assessed studies for inclusion and extracted data for entry in to the RevMan 4.2. Pharmaceutical companies and study investigators were contacted for unpublished trials.

Keputusan Utama

Five studies were included in the review. Trials comparing methotrexate, chloroquine, cyclosporin A and pentoxifylline were identified. No data could be combined for a meta-analysis. Data on lung function, chest x-ray scores and dyspnoea were largely inconclusive. Adverse effects were associated with methotrexate, cyclosporin A, chloroquine and pentoxifylline. In two small studies methotrexate and pentoxifylline were associated with a steroid sparing effect. In the methotrexate study this was apparent after 12 months of therapy, but no difference was observed at 6 months.

Kesimpulan Pengarang

The current body of evidence supporting the use of immunosuppressive agents and cytotoxic therapies is limited. Side-effects associated with some of the therapies were severe.

Petikan
Paramothayan NS, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003536. DOI: 10.1002/14651858.CD003536.pub2.

Penggunaan cookie kami

Kami menggunakan cookie yang diperlukan untuk menjadikan laman web kami berfungsi. Kami juga ingin menetapkan cookie analitik pilihan untuk membantu kami memperbaikinya. Kami tidak akan menetapkan cookie pilihan melainkan anda mengaktifkannya. Menggunakan alat ini akan menetapkan cookie pada peranti anda untuk mengingati pilihan anda. Anda boleh menukar pilihan cookie anda pada bila-bila masa dengan menekan pautan 'Tetapan cookie' di bahagian bawah setiap halaman.
Untuk maklumat lebih terperinci mengenai cookie yang kami gunakan, lihat halaman halaman cookie.

Terima semua
Konfigurasikan